Selectivity and Potency of Agonists for the Three Subtypes of Cloned Human β-Adrenoceptors Expressed in Chinese Hamster Ovary Cells

The selectivities, potencies and efficacies of β3-adrenoceptor (β3-AR) agonists on human three β-AR subtypes expressed in Chinese hamster ovary (CHO) cells were investigated using radioligand binding assay and cyclic AMP (cAMP) accumulation assay. The three β-AR subtypes showed the nature of G prote...

Full description

Saved in:
Bibliographic Details
Published inThe Tohoku Journal of Experimental Medicine Vol. 192; no. 3; pp. 181 - 193
Main Authors Yanagisawa, Teruyuki, Sato, Takeya, Yamada, Hiroaki, Sukegawa, Jun, Nunoki, Kazuo
Format Journal Article
LanguageEnglish
Published Japan Tohoku University Medical Press 01.11.2000
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The selectivities, potencies and efficacies of β3-adrenoceptor (β3-AR) agonists on human three β-AR subtypes expressed in Chinese hamster ovary (CHO) cells were investigated using radioligand binding assay and cyclic AMP (cAMP) accumulation assay. The three β-AR subtypes showed the nature of G protein-coupled receptors with the constitutive activity. BRL37344, CL-316, 243 and a newly synthesized β3-AR agonist N-5984, 6-[2-(R)-[[2-(R)-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-2, 3-dihydro-1, 4-benzodioxine-2-(R)-carboxylic acid, were compared for the potency and selectivity for the β3-AR. In the radioligand binding assay, the affinity of N-5984 for β3-ARs was 14, 70 and 220 times more potent than those of BRL37344, isoproterenol and CL-316, 243, respectively. N-5984 had higher selectivity than BRL37344 for human β3-ARs compared with either for β1-ARs or β2-ARs. N-5984 showed higher potency and intrinsic activity of cAMP production than BRL37344 in CHO cells expressing the β3-ARs. CL-316, 243 had almost no activity of cAMP production in CHO cells expressing any subtype of β-ARs. These results indicate that N-5984 is the most potent and selective agonist for human β3-ARs than any other agonists tested.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0040-8727
1349-3329
DOI:10.1620/tjem.192.181